152.81
2.19 (1.45%)
Previous Close | 150.62 |
Open | 150.42 |
Volume | 434,220 |
Avg. Volume (3M) | 617,018 |
Market Cap | 8,580,067,328 |
Price / Earnings (Forward) | 85.47 |
Price / Sales | 12.19 |
Price / Book | 4.00 |
52 Weeks Range | |
Earnings Date | 29 Apr 2025 - 5 May 2025 |
Profit Margin | -3.53% |
Operating Margin (TTM) | 5.59% |
Diluted EPS (TTM) | -0.420 |
Quarterly Revenue Growth (YOY) | 10.40% |
Quarterly Earnings Growth (YOY) | 76.90% |
Total Debt/Equity (MRQ) | 34.44% |
Current Ratio (MRQ) | 6.79 |
Operating Cash Flow (TTM) | 145.69 M |
Levered Free Cash Flow (TTM) | 183.66 M |
Return on Assets (TTM) | 0.92% |
Return on Equity (TTM) | -1.16% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
Medical Instruments & Supplies (Global) | Bearish | Mixed | |
Stock | Repligen Corporation | Bullish | Bullish |
AIStockmoo Score
Analyst Consensus | 1.5 |
Insider Activity | NA |
Price Volatility | 1.0 |
Technical Moving Averages | 1.5 |
Technical Oscillators | 2.0 |
Average | 1.50 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively. |
|
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Investment Style | Small Core |
% Held by Insiders | 6.44% |
% Held by Institutions | 103.23% |
52 Weeks Range | ||
Price Target Range | ||
High | 190.00 (JP Morgan, 24.34%) | Buy |
Median | 180.00 (17.79%) | |
Low | 150.00 (Canaccord Genuity, -1.84%) | Hold |
Average | 172.80 (13.08%) | |
Total | 3 Buy, 2 Hold | |
Avg. Price @ Call | 139.07 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 05 May 2025 | 180.00 (17.79%) | Buy | 141.51 |
21 Feb 2025 | 180.00 (17.79%) | Buy | 158.99 | |
RBC Capital | 30 Apr 2025 | 189.00 (23.68%) | Buy | 137.99 |
21 Feb 2025 | 205.00 (34.15%) | Buy | 158.99 | |
JP Morgan | 29 Apr 2025 | 190.00 (24.34%) | Buy | 139.43 |
21 Feb 2025 | 200.00 (30.88%) | Buy | 158.99 | |
Canaccord Genuity | 16 Apr 2025 | 150.00 (-1.84%) | Hold | 132.10 |
21 Feb 2025 | 170.00 (11.25%) | Hold | 158.99 | |
Evercore ISI Group | 18 Mar 2025 | 155.00 (1.43%) | Hold | 144.34 |
No data within this time range.
Date | Type | Details |
---|---|---|
07 May 2025 | Announcement | Repligen Corporation to Present at Upcoming May Investor Conferences |
29 Apr 2025 | Announcement | Repligen Reports First Quarter 2025 Financial Results |
15 Apr 2025 | Announcement | Repligen to Report First Quarter 2025 Financial Results |
08 Apr 2025 | Announcement | Repligen Appoints Jacob Johnson As Vice President Investor Relations |
04 Mar 2025 | Announcement | Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices |
04 Mar 2025 | Announcement | Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices |
20 Feb 2025 | Announcement | Repligen Reports Fourth Quarter and Full Year 2024 Financial Results |
11 Feb 2025 | Announcement | Repligen to Report Fourth Quarter and Full Year 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |